Study design.

Abstract

<p>Data of 802 patients were available for analysis (75.3% patients with Crohn's disease and 24.7% patients with ulcerative colitis). In 554 IBD patients, there was no baseline and/or follow-up colonoscopy available. Accordingly, 248 patients were included in the analysis, while 202 patients were treated with one anti-TNF antibody between baseline and follow-up colonoscopy (TNF1 group) and 46 patients were treated with a second anti-TNF antibody after loss of response or intolerance to a first anti-TNF antibody (TNF2 group).</p